CN114599680A - 抗ox40抗体及其用途 - Google Patents
抗ox40抗体及其用途 Download PDFInfo
- Publication number
- CN114599680A CN114599680A CN202080073991.XA CN202080073991A CN114599680A CN 114599680 A CN114599680 A CN 114599680A CN 202080073991 A CN202080073991 A CN 202080073991A CN 114599680 A CN114599680 A CN 114599680A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cancer
- human
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
提供了抗OX40抗体,包含所述抗OX40抗体的组合物,编码所述抗OX40抗体的核酸,制备所述抗OX40抗体的方法,和所述抗OX40抗体的用途。
Description
PCT国内申请,说明书已公开。
Claims (24)
- PCT国内申请,权利要求书已公开。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311188366.1A CN117186231A (zh) | 2019-12-27 | 2020-12-28 | 抗ox40抗体及其用途 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911383060.5A CN113045655A (zh) | 2019-12-27 | 2019-12-27 | 抗ox40抗体及其用途 |
CN2019113830605 | 2019-12-27 | ||
US202063041532P | 2020-06-19 | 2020-06-19 | |
US63/041,532 | 2020-06-19 | ||
PCT/CN2020/140186 WO2021129872A1 (zh) | 2019-12-27 | 2020-12-28 | 抗ox40抗体及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311188366.1A Division CN117186231A (zh) | 2019-12-27 | 2020-12-28 | 抗ox40抗体及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114599680A true CN114599680A (zh) | 2022-06-07 |
CN114599680B CN114599680B (zh) | 2023-09-08 |
Family
ID=76507054
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911383060.5A Pending CN113045655A (zh) | 2019-12-27 | 2019-12-27 | 抗ox40抗体及其用途 |
CN202311188366.1A Pending CN117186231A (zh) | 2019-12-27 | 2020-12-28 | 抗ox40抗体及其用途 |
CN202080073991.XA Active CN114599680B (zh) | 2019-12-27 | 2020-12-28 | 抗ox40抗体及其用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911383060.5A Pending CN113045655A (zh) | 2019-12-27 | 2019-12-27 | 抗ox40抗体及其用途 |
CN202311188366.1A Pending CN117186231A (zh) | 2019-12-27 | 2020-12-28 | 抗ox40抗体及其用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230061604A1 (zh) |
EP (1) | EP4083069A4 (zh) |
JP (1) | JP2023508218A (zh) |
KR (1) | KR20230019065A (zh) |
CN (3) | CN113045655A (zh) |
AU (1) | AU2020412166A1 (zh) |
BR (1) | BR112022012731A2 (zh) |
CA (1) | CA3163126A1 (zh) |
TW (1) | TWI824217B (zh) |
WO (1) | WO2021129872A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
AR126257A1 (es) * | 2021-06-29 | 2023-10-04 | Hifibio Hk Ltd | Anticuerpo monoclonal anti-ox40 y métodos para su uso |
WO2023187468A2 (en) | 2022-03-28 | 2023-10-05 | Hifibio (Hk) Limited | Predictive response biomarker discovery process |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107709367A (zh) * | 2015-05-21 | 2018-02-16 | 鳄鱼生物科学公司 | 新型多肽 |
CN107847570A (zh) * | 2015-05-08 | 2018-03-27 | 优瑞科生物技术公司 | 靶向hpv16‑e7肽/mhc复合体的构建体及其用途 |
WO2018150326A1 (en) * | 2017-02-15 | 2018-08-23 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
WO2019008335A1 (en) * | 2017-07-07 | 2019-01-10 | Avacta Life Sciences Limited | SCAFFOLD PROTEINS |
CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
CN113045654A (zh) * | 2019-12-27 | 2021-06-29 | 南开大学 | 抗ox40抗体及其用途 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
PT1575517E (pt) | 2002-12-24 | 2012-05-28 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR101783004B1 (ko) | 2008-07-08 | 2017-09-28 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸 |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
LT2731677T (lt) * | 2011-07-11 | 2018-07-10 | Glenmark Pharmaceuticals S.A. | Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas |
RS57840B1 (sr) * | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
JP2018512397A (ja) * | 2015-03-11 | 2018-05-17 | プロビデンス ヘルス アンド サービシーズ−オレゴン | 癌治療の有効性を高めるための組成物及び方法 |
CA2987410A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
CN108137684B (zh) * | 2015-10-15 | 2022-03-08 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
WO2019028182A2 (en) * | 2017-08-01 | 2019-02-07 | Remd Biotherapeutics, Inc. | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) |
CN110467674B (zh) * | 2018-05-11 | 2022-05-31 | 同润澳门一人有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
-
2019
- 2019-12-27 CN CN201911383060.5A patent/CN113045655A/zh active Pending
-
2020
- 2020-12-28 CA CA3163126A patent/CA3163126A1/en active Pending
- 2020-12-28 EP EP20907635.5A patent/EP4083069A4/en active Pending
- 2020-12-28 WO PCT/CN2020/140186 patent/WO2021129872A1/zh unknown
- 2020-12-28 CN CN202311188366.1A patent/CN117186231A/zh active Pending
- 2020-12-28 BR BR112022012731A patent/BR112022012731A2/pt unknown
- 2020-12-28 JP JP2022539717A patent/JP2023508218A/ja active Pending
- 2020-12-28 US US17/789,350 patent/US20230061604A1/en active Pending
- 2020-12-28 KR KR1020227025959A patent/KR20230019065A/ko unknown
- 2020-12-28 AU AU2020412166A patent/AU2020412166A1/en active Pending
- 2020-12-28 CN CN202080073991.XA patent/CN114599680B/zh active Active
- 2020-12-28 TW TW109146459A patent/TWI824217B/zh active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107847570A (zh) * | 2015-05-08 | 2018-03-27 | 优瑞科生物技术公司 | 靶向hpv16‑e7肽/mhc复合体的构建体及其用途 |
CN107709367A (zh) * | 2015-05-21 | 2018-02-16 | 鳄鱼生物科学公司 | 新型多肽 |
WO2018150326A1 (en) * | 2017-02-15 | 2018-08-23 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
WO2019008335A1 (en) * | 2017-07-07 | 2019-01-10 | Avacta Life Sciences Limited | SCAFFOLD PROTEINS |
CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
CN113045654A (zh) * | 2019-12-27 | 2021-06-29 | 南开大学 | 抗ox40抗体及其用途 |
Non-Patent Citations (1)
Title |
---|
REUE,A等: "HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy" * |
Also Published As
Publication number | Publication date |
---|---|
AU2020412166A1 (en) | 2022-07-21 |
US20230061604A1 (en) | 2023-03-02 |
CA3163126A1 (en) | 2021-07-01 |
CN114599680B (zh) | 2023-09-08 |
JP2023508218A (ja) | 2023-03-01 |
CN117186231A (zh) | 2023-12-08 |
CN113045655A (zh) | 2021-06-29 |
EP4083069A1 (en) | 2022-11-02 |
TWI824217B (zh) | 2023-12-01 |
TW202136313A (zh) | 2021-10-01 |
BR112022012731A2 (pt) | 2022-10-11 |
WO2021129872A1 (zh) | 2021-07-01 |
KR20230019065A (ko) | 2023-02-07 |
EP4083069A4 (en) | 2024-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7450592B2 (ja) | 癌治療におけるfgfr2阻害剤単独または免疫刺激剤との組み合わせ | |
US20180362443A1 (en) | Uses of anti-her3 antibodies for treating cancer | |
TWI803637B (zh) | 特異性針對gucy2c之抗體及其用途 | |
JP6840127B2 (ja) | がんの治療における抗pd−1抗体および抗m−csf抗体の併用 | |
CN114599680B (zh) | 抗ox40抗体及其用途 | |
JP2017514461A (ja) | 抗ox40抗体及び使用方法 | |
US20170190788A1 (en) | Uses of anti-her3 antibodies for treating cancer | |
KR20210030957A (ko) | 항-메소텔린 항체 | |
TW201811826A (zh) | 抗icos抗體 | |
AU2018323955A1 (en) | Anti-LAG-3 antibodies and uses thereof | |
WO2021129874A1 (zh) | 抗ox40抗体及其用途 | |
JP2023103352A (ja) | 抗原結合タンパク質 | |
JP2022554270A (ja) | 抗pd-1抗体による癌を治療する方法 | |
AU2022305518A1 (en) | Anti-ox40 monoclonal antibody and methods of use thereof | |
WO2023001118A1 (zh) | 抗ox40抗体在联合用药中的应用 | |
KR20230154315A (ko) | 항체의 신규한 조합물 및 이의 용도 | |
JP2023537115A (ja) | 抗cd73抗体を使用する癌処置方法 | |
CN117957253A (zh) | 癌症的组合治疗中针对cd40和cd137的多特异性结合剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40074868 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |